Biography
Dr. Khozin is an oncologist and physician-scientist, currently serving as Chief Executive Officer of CancerLinQ, a company focused on advancing cancer care quality and research. Previously, he was Global Head of Data Strategy and Data Science Innovation at J&J, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative medicines. Before joining J&J, Dr. Khozin led FDA Oncology Center of Excellence’s bioinformatics, regulatory science, and clinical trial innovation efforts and was the founding Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that played a pivotal role in the agency’s technology modernization efforts. Before his tenure in federal government, Dr. Khozin was the cofounder of Hello Health, a company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical systems for optimizing patient care and clinical research.

Biography
Patrick Loerch has over 20 years of experience in data sciences, real world evidence and genomics research spanning all phases of R&D within the pharmaceutical industry. Dr Loerch currently serves as Senior Vice President, Clinical Data Sciences at Gilead Sciences. In addition to oversight of the Biometrics, Clinical Bioinformatics and Real World Evidence organizations, Dr. Loerch is accountable for the build out and integration of Enterprise Data Sciences capabilities to accelerate the discovery, development and delivery of new medicines. Dr. Loerch’s prior roles include leadership positions at Johnson & Johnson, Celgene and Merck. He began his career at Rosetta Inpharmatics, a genomics start-up in Seattle, WA that was later acquired by Merck. Dr. Loerch received his PhD in Biostatistics from the Harvard University and his BS in Biochemistry from Washington State University.

Biography
Chris developed the technology and approach that seeded Recursion as part of his MD/PhD work in the lab of Co-Founder Dr. Dean Li (current President of Merck Research Labs) while at the University of Utah. After completing his Ph.D., Chris left medical school to build Recursion into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and management. Chris serves on the Board of BioUtah and is the Chair of BioHive, the public-private partnership driving expansion of Utah's life-science ecosystem, the fastest growing in the nation. Chris is also active as an advisor and mentor, both formally and informally, of many young biotech founders. Chris enjoys cycling on both the road and the trails that cut through Utah's great wilderness, as well as spending time with family.

Biography
Dr Lungren was an interventional radiologist and research faculty at Stanford University Medical School where he led the Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI). He served as advisor for dozens of early stage startups and large fortune-500 companies on healthcare AI go-to-market strategy. His work has led to more than 100 scientific publications. Dr. Lungren is frequently featured in national news outlets such as NPR, Vice News, Scientific American, and he regularly speaks at national and international scientific meetings on the topic of AI in healthcare. Finally, Dr. Lungren is also a top rated instructor on Coursera where his AI in Healthcare course designed especially for learners with non-technical backgrounds has been completed by more than 10k students around the world.

Biography
Greg invests in teams trying to solve major problems in life science and digital health, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Prior to entering investing, Greg served for more than 20 years in senior executive and entrepreneurial roles in life sciences and digital health. He was CEO and co-founder of two startups (Biodesy in protein analysis & therapeutics and PyrAmes in digital health & remote monitoring). At Roche/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg was also an EIR at Illumina Ventures, the first healthcare EIR at GE, VP/GM at Affymetrix, and consultant for McKinsey. Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton and his MBA from Stanford. Greg is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership network.

Biography
Dr. The is a leader in our Life Sciences practice, where she serves biotechs and pharmacos on R&D strategy. She is also a leader in overall service line for high-growth biotech clients. She is a leader in McKinsey’s Center for Asset Optimization where she develop R&D strategy, for platform technologies, portfolios and individual assets. In the past ten years, she has developed portfolio and platform strategies for 20+ biopharma companies. Throughout her work, she focus on helping companies deliver transformational therapies to maximize patient benefit. She received her Ph.D. in Molecular & Cell Biology at UC Berkeley, where she studied the molecular mechanisms of atopic dermatitis and was supported by an NSF Graduate Research Fellowship.

Biography
Andrea Mazzocchi, PhD completed her PhD in biomedical engineering from Wake Forest School of Medicine and received her BS in Biomedical Engineering from Rochester Institute of Technology. She has spent the past several years focused on cancer biology, tissue engineering, and biomaterials. Her research has focused on the intersection of these fields to generate a cancer precision medicine platform. Known Medicine marries this patient-specific wetlab approach with data science to generate biological, computational, and clinical insights to improve cancer patient lives.